IndraLab
Statements
sparser
"The lead compound they developed is a dimeric quinacrine (DQ661), which is derived from Lys05, has improved lysosomal targeting capability and impairs the activity of palmitoyl-protein thioesterase (PPT1), which is required for mTOR interaction with Rheb at the lysosome [ xref ]; inhibition of PPT1 also prevents mTORC1 from associating with the lysosomal membrane, causing mTOR inhibition [ xref ]."